Social Europe

politics, economy and employment & labour

  • Themes
    • Strategic autonomy
    • War in Ukraine
    • European digital sphere
    • Recovery and resilience
  • Publications
    • Books
    • Dossiers
    • Occasional Papers
    • Research Essays
    • Brexit Paper Series
  • Podcast
  • Videos
  • Newsletter

Fighting Covid-19 requires fewer patents and more state

Piergiuseppe Fortunato 20th July 2021

Big Pharma has not been the real innovator in the fight against the pandemic and intellectual property rights must be reshaped to restore fairness.

vaccines,Pfizer,patents,Big Pharma
Piergiuseppe Fortunato

On March 17th 2020, the pharmaceutical giant Pfizer officially partnered with Biopharmaceutical New Technologies (BioNTech), a spinoff of the Johannes Gutenberg-University of Mainz. The partnership was to accelerate a potential first-in-class Covid-19 vaccine (BNT162), using not attenuated or deactivated virus but a strand of messenger ribonucleic acid (mRNA) to produce, and engender immunity against, the virus’ spike protein.

The vaccine was expected to enter clinical testing by the end of the following month. At that point, it had already been almost entirely developed by the small German immunotherapy company. What Pfizer brought to the alliance was essentially funds for the clinical trials and commercial capabilities.

In September, BioNTech was granted around $445 million from the German Ministry of Education and Research, to advance its  programme through regulatory approvals. These funds compounded the over $120 million already received by the company as concessionary lending by the European Investment Bank. Meanwhile, Pfizer secured an upfront payment of nearly $2 billion from the United States government for 100 million doses of the vaccine. As with other massive vaccine producers, and responding to a call by pharmaceutical companies in the early stages of the pandemic, the deal was intended to share part of the risks inherent in vaccine development and distribution.

Secondary contribution

The BioNTech/Pfizer story is not an exception. Vaccine-research programmes, as with all research in the bio-pharma sector, rely significantly on public investments in the basic science and, at a later stage, on public support and supervision for clinical trials and regulatory approvals. For almost all SARS-CoV-2 vaccine candidates which have reached advanced stages of testing, the contribution of the large pharmaceutical companies has been only secondary.


Our job is keeping you informed!


Subscribe to our free newsletter and stay up to date with the latest Social Europe content. We will never send you spam and you can unsubscribe anytime.

Sign up here

Giants such as Merck and Sanofi are still lagging, while AstraZeneca only came into play when the vaccine developed by Oxford University—almost entirely publicly funded—entered the phase of clinical testing and production, just as with Pfizer. To date the only large private company able to develop a vaccine on its own account (neither the first nor the most effective) is Johnson & Johnson, through its Belgian subsidiary Janssen Pharmaceuticals. The real innovators in the fight against Covid-19 have been universities or small businesses which are essentially spinoffs of academic research, as with BioNTech or Moderna.

Despite an essentially supporting role all through the innovation process, Big Pharma can quite paradoxically claim almost exclusive intellectual-property rights (IPR) over innovations and capture notable rents on the products they manufacture. During the first quarter of 2021, the vaccine was, far and away, Pfizer’s biggest source of revenue, bringing in over $3.5 billion. These revenues came by selling most of the doses to deep-pocketed governments in north America and Europe.

Indeed, Pfizer, along with the rest of the industry, has been lobbying to stop a temporary waiver of IPR, endorsed by the current US administration under Joe Biden, to allow generic Covid-19 vaccines to be distributed at low cost in the global south. Instead, the industry is asserting monopoly rights in all those developing economies that ratified the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which came into force back in 1995—even at the cost of delaying Covid-19 immunisation worldwide.

Market power

Claims to IPR—via patents, copyrights and trademarks—have become one of the main means of enhancing market power, and thereby appropriating greater rents, often at the expense of wider public interests. Patent filings stood at one million in 1995. By 2011 they had more than doubled. In 2014 they reached around ten million, valued at around $15 trillion.

Since productivity in research and development has however been declining globally, IPR are apparently being disproportionately asserted to benefit incumbent firms in core and secondary markets. According to the Organisation for Economic Co-operation and Development, the average technological and economic value of inventions protected by patents has eroded, while the legal right to exclude others has become broad and susceptible to abuse.

Two specific practices are patent thickets (overlapping patents covering a wide area of economic activity and potential downstream inventions) and patent fencing (excessive patenting with a view to cordoning off areas of future research). Between 1990 and 2005, Pfizer filed around 50 patents in several different categories (substance, process, formulation/dosing, combination and use) to defend its market position on PDE5 inhibitors, used to treat male erectile dysfunction. Patent thickets and fencing expand protection over entire technological domains, maintaining the advantage of incumbent firms at the cost of potentially slowing the overall pace of innovation.

Public sector

The primacy granted to private investor interests is also questionable considering the role played, in several industries, by fundamental and applied research in the public sector. Many breakthrough technologies emanating from the US National Institute of Health, the National Science Foundation and the Defense Advanced Research Projects Agency—which funded what became the internet when it was trying to create a wireless network to connect the dispersed cogs of the US military machine—ultimately benefited companies in the biochemical industry or in Silicon Valley. Leveraging the patent system enshrined in TRIPS, they obtained enormous positional rents.

Patenting vaccines (and drugs) is particularly problematic, since public research irrigation is preponderant and large companies typically come into play only in the phase of clinical trials, right before patenting, usually when the resources to be invested exceed the financial capacities of small inventors. The pricing of the patented products, however, does not internalise the contribution by other actors, including public institutions, or public-health objectives (such as global immunisation in the case of Covid-19), since the IPR system has not been designed to do so. On the contrary, being subject to intense lobbying and regulatory capture by large companies, the system is often abused and high prices persist, granting to the privileged holders profits not justifiable by their contribution.


We need your support


Social Europe is an independent publisher and we believe in freely available content. For this model to be sustainable, however, we depend on the solidarity of our readers. Become a Social Europe member for less than 5 Euro per month and help us produce more articles, podcasts and videos. Thank you very much for your support!

Become a Social Europe Member

This is as socially inequitable as it is economically inefficient—its inadequacy dramatically exposed by the pandemic. Vaccines developed with substantial public contributions are generating hundreds of billions of dollars in sales for the pharmaceutical companies, while the coronavirus is still ravaging poorer nations which cannot afford immunisation.

Correcting these distortions would require simultaneously rethinking the patent system and the role of the state. Large private manufactures would then produce generic vaccines and drugs, priced accordingly, while governments would more explicitly steer research and innovation, conducting (rather than merely co-funding and supervising) clinical trials and testing. Waiving TRIPS would represent a first step.

Piergiuseppe Fortunato
Piergiuseppe Fortunato

Piergiuseppe Fortunato is an economist at the United Nations Conference on Trade and Development, where he leads projects on global value chains and economic integration, and an external professor of political economics at the Université de Neuchâtel.

You are here: Home / Politics / Fighting Covid-19 requires fewer patents and more state

Most Popular Posts

Visentini,ITUC,Qatar,Fight Impunity,50,000 Visentini, ‘Fight Impunity’, the ITUC and QatarFrank Hoffer
Russian soldiers' mothers,war,Ukraine The Ukraine war and Russian soldiers’ mothersJennifer Mathers and Natasha Danilova
IGU,documents,International Gas Union,lobby,lobbying,sustainable finance taxonomy,green gas,EU,COP ‘Gaslighting’ Europe on fossil fuelsFaye Holder
Schengen,Fortress Europe,Romania,Bulgaria Romania and Bulgaria stuck in EU’s second tierMagdalena Ulceluse
income inequality,inequality,Gini,1 per cent,elephant chart,elephant Global income inequality: time to revise the elephantBranko Milanovic

Most Recent Posts

Pakistan,flooding,floods Flooded Pakistan, symbol of climate injusticeZareen Zahid Qureshi
reality check,EU foreign policy,Russia Russia’s invasion of Ukraine: a reality check for the EUHeidi Mauer, Richard Whitman and Nicholas Wright
permanent EU investment fund,Recovery and Resilience Facility,public investment,RRF Towards a permanent EU investment fundPhilipp Heimberger and Andreas Lichtenberger
sustainability,SDGs,Finland Embedding sustainability in a government programmeJohanna Juselius
social dialogue,social partners Social dialogue must be at the heart of Europe’s futureClaes-Mikael Ståhl

Other Social Europe Publications

front cover scaled Towards a social-democratic century?
Cover e1655225066994 National recovery and resilience plans
Untitled design The transatlantic relationship
Women Corona e1631700896969 500 Women and the coronavirus crisis
sere12 1 RE No. 12: Why No Economic Democracy in Sweden?

ETUI advertisement

The EU recovery strategy: a blueprint for a more Social Europe or a house of cards?

This new ETUI paper explores the European Union recovery strategy, with a focus on its potentially transformative aspects vis-à-vis European integration and its implications for the social dimension of the EU’s socio-economic governance. In particular, it reflects on whether the agreed measures provide sufficient safeguards against the spectre of austerity and whether these constitute steps away from treating social and labour policies as mere ‘variables’ of economic growth.


DOWNLOAD HERE

Eurofound advertisement

Eurofound webinar: Making telework work for everyone

Since 2020 more European workers and managers have enjoyed greater flexibility and autonomy in work and are reporting their preference for hybrid working. Also driven by technological developments and structural changes in employment, organisations are now integrating telework more permanently into their workplace.

To reflect on these shifts, on 6 December Eurofound researchers Oscar Vargas and John Hurley explored the challenges and opportunities of the surge in telework, as well as the overall growth of telework and teleworkable jobs in the EU and what this means for workers, managers, companies and policymakers.


WATCH THE WEBINAR HERE

Foundation for European Progressive Studies Advertisement

The winter issue of the Progressive Post magazine from FEPS is out!

The sequence of recent catastrophes has thrust new words into our vocabulary—'polycrisis', for example, even 'permacrisis'. These challenges have multiple origins, reinforce each other and cannot be tackled individually. But could they also be opportunities for the EU?

This issue offers compelling analyses on the European health union, multilateralism and international co-operation, the state of the union, political alternatives to the narrative imposed by the right and much more!


DOWNLOAD HERE

Hans Böckler Stiftung Advertisement

The macroeconomic effects of re-applying the EU fiscal rules

Against the background of the European Commission's reform plans for the Stability and Growth Pact (SGP), this policy brief uses the macroeconometric multi-country model NiGEM to simulate the macroeconomic implications of the most relevant reform options from 2024 onwards. Next to a return to the existing and unreformed rules, the most prominent options include an expenditure rule linked to a debt anchor.

Our results for the euro area and its four biggest economies—France, Italy, Germany and Spain—indicate that returning to the rules of the SGP would lead to severe cuts in public spending, particularly if the SGP rules were interpreted as in the past. A more flexible interpretation would only somewhat ease the fiscal-adjustment burden. An expenditure rule along the lines of the European Fiscal Board would, however, not necessarily alleviate that burden in and of itself.

Our simulations show great care must be taken to specify the expenditure rule, such that fiscal consolidation is achieved in a growth-friendly way. Raising the debt ceiling to 90 per cent of gross domestic product and applying less demanding fiscal adjustments, as proposed by the IMK, would go a long way.


DOWNLOAD HERE

ILO advertisement

Global Wage Report 2022-23: The impact of inflation and COVID-19 on wages and purchasing power

The International Labour Organization's Global Wage Report is a key reference on wages and wage inequality for the academic community and policy-makers around the world.

This eighth edition of the report, The Impact of inflation and COVID-19 on wages and purchasing power, examines the evolution of real wages, giving a unique picture of wage trends globally and by region. The report includes evidence on how wages have evolved through the COVID-19 crisis as well as how the current inflationary context is biting into real wage growth in most regions of the world. The report shows that for the first time in the 21st century real wage growth has fallen to negative values while, at the same time, the gap between real productivity growth and real wage growth continues to widen.

The report analysis the evolution of the real total wage bill from 2019 to 2022 to show how its different components—employment, nominal wages and inflation—have changed during the COVID-19 crisis and, more recently, during the cost-of-living crisis. The decomposition of the total wage bill, and its evolution, is shown for all wage employees and distinguishes between women and men. The report also looks at changes in wage inequality and the gender pay gap to reveal how COVID-19 may have contributed to increasing income inequality in different regions of the world. Together, the empirical evidence in the report becomes the backbone of a policy discussion that could play a key role in a human-centred recovery from the different ongoing crises.


DOWNLOAD HERE

About Social Europe

Our Mission

Article Submission

Membership

Advertisements

Legal Disclosure

Privacy Policy

Copyright

Social Europe ISSN 2628-7641

Social Europe Archives

Search Social Europe

Themes Archive

Politics Archive

Economy Archive

Society Archive

Ecology Archive

Follow us

RSS Feed

Follow us on Facebook

Follow us on Twitter

Follow us on LinkedIn

Follow us on YouTube